文献速递肝病

利用肝脏硬度预测和监测酒精相关肝病患者失代偿与死亡风险

Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
PubMed 文献 · J Hepatol · 2024-02-28

该观察性队列研究纳入丹麦和奥地利536例有酒精相关肝病风险的代偿期患者,评估瞬时弹性成像肝脏硬度测量(LSM)及其中位2年后的变化对失代偿和全因死亡的预测价值。基线LSM、随访LSM及LSM变化对失代偿和死亡均有较好预测能力;cACLD增量组较cACLD减量组失代偿和死亡风险显著更高。

要点

  • 基线LSM、随访LSM及LSM变化均可预测失代偿和全因死亡。
  • cACLD增量组较cACLD减量组失代偿风险更高(sHR 4.39,p=0.004)。
  • cACLD增量组较cACLD减量组死亡风险更高(HR 3.22,p=0.01)。

核心结论

  • 瞬时弹性成像LSM在代偿期ALD患者诊断时及监测中均可预测失代偿和全因死亡。

研究设计与样本

  • 丹麦和奥地利代偿期有ALD风险患者的观察性队列研究,随访536例患者共3008患者年。
  • 中位年龄57岁(IQR 49-63),基线LSM 8.1 kPa(IQR 4.9-21.7)。
  • 371例(69%)在中位25个月(IQR 17-38)后接受随访LSM。

主要发现

  • 随访期间41例失代偿、55例死亡。
  • 基线125例cACLD患者中14%为cACLD增量者、43%为cACLD减量者;无cACLD患者中13%(33/246)为无cACLD增量者。
  • 基线LSM、随访LSM和LSM变化预测失代偿的C-index分别为0.85、0.89和0.85,预测死亡的C-index分别为0.74、0.74和0.70。
  • cACLD增量者较cACLD减量者无失代偿生存显著更低,失代偿风险更高(sHR 4.39,p=0.004),死亡风险更高(HR 3.22,p=0.01)。

关键数值与推荐

  • cACLD定义为基线LSM≥10 kPa。
  • cACLD增量者定义为LSM增加≥20%。
  • cACLD减量者定义为随访LSM<10 kPa或<20 kPa且LSM下降≥20%。
  • 无cACLD增量者定义为随访LSM≥10 kPa。

临床怎么用

  • Baveno VII推荐LSM用于慢性肝病包括ALD的疾病预后和监测。
  • 作者指出LSM及LSM变化支持其用于ALD的疾病预后和监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver stiffness measurement (LSM) is recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients with alcohol-related liver disease (ALD). METHODS: We performed an observational cohort study of compensated patients at risk of ALD from Denmark and Austria. We evaluated the risk of decompensation and all-cause mortality, stratified for compensated advanced chronic liver disease (cACLD: baseline LSM ≥10 kPa) and LSM changes after a median of 2 years. In patients with cACLD, we defined LSM changes as (A) LSM increase ≥20% ("cACLD increasers") and (B) follow-up LSM <10 kPa or <20 kPa with LSM decrease ≥20% ("cACLD decreasers"). In patients without cACLD, we defined follow-up LSM ≥10 kPa as an LSM increase ("No cACLD increasers"). The remaining patients were considered LSM stable. RESULTS: We followed 536 patients for 3,008 patient-years-median age 57 years (IQR 49-63), baseline LSM 8.1 kPa (IQR 4.9-21.7)-371 patients (69%) had follow-up LSM after a median of 25 months (IQR 17-38), 41 subsequently decompensated and 55 died. Of 125 with cACLD at baseline, 14% were "cACLD increasers" and 43% "cACLD decreasers", while 13% of patients without cACLD were "No cACLD increasers" (n = 33/246). Baseline LSM, follow-up LSM and LSM changes accurately predicted decompensation (C-index: baseline LSM 0.85; follow-up LSM 0.89; LSM changes 0.85) and mortality (C-index: baseline LSM 0.74; follow-up LSM 0.74; LSM changes 0.70). When compared to "cACLD decreasers", "cACLD increasers" had significantly lower decompensation-free survival and higher risks of decompensation (subdistribution hazard ratio 4.39, p = 0.004) and mortality (hazard ratio 3.22, p = 0.01). CONCLUSION: LSM by transient elastography predicts decompensation and all-cause mortality in patients with compensated ALD both at diagnosis and when used for monitoring. IMPACT AND IMPLICATIONS: Patients at risk of alcohol-related liver disease (ALD) are at significant risk of progressive disease and adverse outcomes. Monitoring is essential for optimal disease surveillance and patient guidance, but non-invasive monitoring tools are lacking. In this study we demonstrate that liver stiffness measurement (LSM), using transient elastography, and LSM changes after a median of 2 years, can predict decompensation and all-cause mortality in patients at risk of ALD with and without compensated advanced chronic liver disease. These findings are in line with results from non-alcoholic fatty liver disease, hepatitis C and primary sclerosing cholangitis, and support the clinical utility of LSM, using transient elastography, for disease prognostication and monitoring in chronic liver diseases including ALD, as recommended by the Baveno VII.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Thorhauge KH, Semmler G, Johansen S, et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol. 2024. PMID: 38428644. doi:10.1016/j.jhep.2024.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。